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Bridge the Gap Between
Chest Pain and Nonobstructive
Coronary Atherosclerosis?*
Sang-Yong Yoo, MD, PHD,y Habib Samady, MDzE valuation of chest pain can be one of the mostchallenging scenarios faced by cardiologists.The differential diagnosis of chest pain
includes myocardial ischemia and pericardial, muscu-
loskeletal, gastrointestinal, pulmonary, or psycholog-
ically related syndromes. Our current diagnostic
pathway includes the clinical history in the context
of the cardiovascular risk factors, noninvasive stress
testing, or computed tomography angiography, fol-
lowed by invasive coronary angiography when these
tests indicate signiﬁcant ischemia. Yet 30% to 50%
of patients who undergo angiography are found to
have nonobstructive epicardial disease (1). This high
rate of nonobstructive disease seen on angiography
is often attributed to false-positive stress test results
and is sometimes considered a failure of our clinical
processes. For some patients, the “negative” angiog-
raphy allows reassurance and pursuit of nonischemic
causes of chest pain. Other patients with persistent
chest pain and nonobstructive disease frequently pre-
sent to emergency departments, requiring recurrent
evaluation.
Among patients with persistent chest pain and
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of this paper to disclose.clinical syndromes may have underlying myocardial
ischemia. Those with exercise-induced angina may
have diffuse unappreciated epicardial atheroscle-
rosis, myocardial bridging, coronary microvascular
disease, or exercise-induced vasospasm (2,3). Pa-
tients with rest or mental stress–induced angina
pain may have severe endothelial dysfunction or
coronary vasospasm, and those with mixed chest pain
syndromes may have any combination of these con-
ditions. There is confusion over the nomenclature of
these latter syndromes, which have been variably
called syndrome X, vasospastic angina, variant
angina, Prinzmetal angina, microvascular angina,
endothelial dysfunction, and coronary microvascular
disease. Although the diagnosis and management of
these patients are often difﬁcult for patient and
physician, an accurate diagnosis can be extremely
important to deﬁnitively exclude identiﬁable
ischemic disease or, conversely, to vindicate the pa-
tient’s symptoms when pathology is identiﬁed and
help guide medical therapy.
So where are we with advanced functional or
physiological testing for the diagnosis of coronary
microvascular and endothelial dysfunction in 2015?
Advances in our understanding of the vascular
biology of coronary atherosclerosis and physiology, in
concert with technological advances in our equip-
ment, have been leveraged to develop new diagnostic
tests. Noninvasive imaging techniques, including
cardiac magnetic resonance imaging, cardiac positron
emission tomography, single-photon emission com-
puted tomography, and contrast echocardiography,
can provide an aggregate of baseline and hyperemic
ﬂow within the myocardial bed; however, only
invasive diagnostic testing can tease out the
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1455relative contribution of endothelium-dependent and
endothelium-independent pathways within the
epicardial vessels and microvasculature. Hemody-
namically signiﬁcant unappreciated epicardial dis-
ease can be excluded by a fractional ﬂow reserve
>0.80, an instantaneous wave-free ratio >0.90, or
hyperemic stenosis resistance <0.8 mm Hg/cm/s.
Coronary ﬂow reserve (CFR) <2.5 in the context of
nonobstructive epicardial disease signiﬁes reduced
aggregate epicardial and microvascular ﬂow. Novel
indexes of microvascular function include the index
of microcirculatory resistance and hyperemic micro-
vascular resistance. To evaluate epicardial and
microvascular endothelial dysfunction or coronary
vasospasm, provocative testing using acetylcholine
(off-label in the United States) or ergonovine (ergo-
metrine may be an alternative in the United States)
may be performed.
Because these patients have persistent symptoms,
an adverse prognosis similar to those with obstructive
disease require additional attention and experience,
few specialized centers of advanced physiological
testing have emerged for their management. Yet the
literature supporting such testing is sparse (4).SEE PAGE 1445In this issue of JACC: Cardiovascular Interventions,
Sara et al. (5) report on the largest experience of invasive
microvascular and endothelial function testing in
symptomatic patients with nonobstructive atheroscle-
rosis to date. In total, 1,439 patients with non-
obstructive angiographic disease (<40% diameter
stenosis by angiography) underwent physiological
testing over 20 years. All patients underwent evaluation
of endothelium-dependent function using intra-
coronary acetylcholine infusions and endothelium-
independent function using intracoronary bolus
injections of adenosine. Impairment of endothelium-
dependent microvascular function was deﬁned as a
maximal percentage increase in coronary blood ﬂow in
response to any dose of acetylcholine compared with
baseline of #50%. Impaired endothelium-independent
microvascular function was deﬁned as a CFR of #2.5.
Patients were divided into 4 groups: patients with
normalmicrovascular function; patients with abnormal
endothelium-dependent and normal endothelium-
independent function; patients with abnormal
endothelium-independent and normal endothelium-
dependent function; and patients with both
abnormal endothelium-dependent and endothelium-
independent function. They found coronary micro-
vascular abnormalities in 63.9%, with more female
than male patients (65.7% vs. 60.4%, p ¼ 0.043).However, after adjusting for other traditional
cardiovascular risk factors, age was the only inde-
pendent predictor of abnormal microvascular
function. Aging is known to be associated with
functional changes of the coronary microvasculature
by reducing synthesis/release and increasing the
breakdown of nitric oxide in the endothelium.
Another interesting ﬁnding of this study is that the
microvascular status of the patient correlated poorly
with conventional cardiovascular risk factors and
was dissociated from the ﬁndings of noninvasive
functional testing. The authors conclude that their
study supports the role of invasive coronary phar-
macological provocation testing to comprehensively
assess coronary microvascular function in patients
with chest pain and nonobstructive coronary artery
disease.
Several limitations of this study should be pointed
out. First, the 63.9% incidence of physiological
abnormality should be interpreted in light of the
referral bias for advanced physiological testing and
likely represents a selected group of patients. The
authors provide limited data on the details of patient
symptomatology. What percentage of patients had
typical exertional angina, atypical angina, mental
stress–induced chest pain, or noncardiac sounding
chest pain? The true prevalence of microvascular or
endothelial dysfunction among all patients with
persistent chest pain and nonobstructive disease is
likely <63.9%. One could evaluate this more accu-
rately by performing invasive testing in consecutive
patients with ischemic sounding chest pain and not
selected patients as performed in this study. Second,
only 24% of all study patients had documented
myocardial ischemia. Although conventional stress
testing may have limited diagnostic power in this
population, recent advances in noninvasive assess-
ment including measurement of CFR with positron
emission tomography or cardiac magnetic resonance
imaging, 6-lead ambulatory electrocardiographic
monitoring, or a steepening of the heart rate–to–
oxygen consumption (VO2) uptake slope on cardio-
pulmonary stress testing may provide evidence of
myocardial ischemia. Other promising noninvasive
tests include pulsatile arterial tonometry, forearm
blood ﬂow vasodilation studies, as well as some novel
vascular biomarkers.
In this study, CFR was measured using intra-
coronary bolus injections and not intravenous or
intracoronary infusion of adenosine, which is
considered the gold standard. Both CFR and endo-
thelial function are continuums, and any dichoto-
mous cutoffs, albeit reasonable based on the limited
available literature, are arbitrary. In addition, the
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1456value of CFR and endothelial function reserve for
every patient may vary over time. It is therefore
difﬁcult to interpret a single value without the
context of the patient’s baseline value. Few serial
data exist on patient-speciﬁc changes in these
measures with aging other than they likely det-
eriorate over time. Another methodological issue
is that the potential role of endothelium-derived
hyperpolarizing factor (EDHF) was not explored in
this study. EDHF is believed to play an important
role in the regulation of coronary blood ﬂow and to
have an important role, even when the nitric oxide
pathway is impaired. Endothelial vasodilator func-
tions are heterogeneous depending on the vessel
size, with a relatively greater role of nitric oxide in
conduit arteries and a predominant role of EDHF in
resistance arteries (6). Finally, this investigation
would have been strengthened by providing serum
biomarker or intravascular imaging data linking
symptoms to physiological response in the cath lab.
Clearly, prospectively relating these biological re-
sponses in the cath lab to clinical outcomes is
necessary.Nevertheless, this study represents a detailed
and comprehensive evaluation of a large number of
patients undergoing detailed invasive physiological
testing by experienced investigators and clinicians.
The paper makes an important contribution to our
understanding of the substantial prevalence and
predictors of coronary microvascular and endothelial
dysfunction. The lack of correlation with cardio-
vascular risk factors and noninvasive stress testing
underscores the value of invasive physiological
testing in appropriately selected patients. Large
multicenter registries with prospectively collected
clinical, biochemical, genetic, and invasive physio-
logical data are warranted to further our under-
standing of this challenging patient population.
Functional coronary angiography will likely have an
integral role in the diagnosis of patients with chest
pain and nonobstructive coronary atherosclerosis.
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